DeepMirror, a University of Cambridge spin-out company developing intuitive design software for the discovery of novel therapeutic drugs, launched its Early Access Programme on 11 December 2023 after a successful closed beta programme during which chemists were invited to test the software over several months. The software allows users to tap into AI-driven insights to […]
Author Archive for: panglobal
This author has yet to write their bio.
Entries by panglobal
Biotium has launched Biotium Choice primary antibody conjugates. With careful curation and extensive in-house validation, Biotium Choice monoclonal primary antibodies are designed to deliver exceptional performance for flow cytometry.
Azenta Life Sciences popular FrameStar 96-well Skirted PCR plate is now available in a wide range of colours (purple, blue, clear, green, red, black, and white) to enable easy visual identification in multi-user labs. Whether you work in a busy pathology, molecular diagnostics, or academic lab, assigning different coloured PCR plates can be a real […]
Leading computational biology company PrecisionLife, which is driving precision medicine in complex chronic diseases, the ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) charity Action for M.E., and the MRC Human Genetics Unit at the Institute of Genetics and Cancer, University of Edinburgh, have been awarded a £622,000 (about US$794,000) grant by Innovate UK’s Advancing Precision Medicine programme […]
Antabio SAS, a clinical stage biopharmaceutical company developing novel treatments for severe drug-resistant bacterial infections, has raised €25 million in a Series B financing round, which will enable the company to complete the phase 2 clinical studies of MEM-ANT3310, a next generation antibacterial.
Metrion Biosciences, a specialist ion channel CRO and drug discovery company, has secured £3.5 million (about US$3,19 million) in new equity financing, including £2.5m from lead investor Maven Capital Partners and £1 million from existing investor, Gresham House Ventures. The funding will be used to further expand Metrion’s laboratories in Cambridge, UK, invest in specialist […]
Aptamer Group, the developer of novel Optimer binders to enable innovation in the life sciences industry, has entered into a material agreement with a biotechnology company developing genetic medicines.
ProBioGen’s Transposase binds to specific epigenetic histone marks characteristic for highly active genome regions. Omitting the plasmid backbone, multiple transposable elements carrying the transgene cassette are specifically inserted resulting in highly stable and high expressing clones.
On 1 December 2023, Ana-Maria Šimundić took up the newly created position as director of Global Medical & Clinical Affairs at Greiner Bio-One. In this role, she will represent Greiner Bio-One in national and international professional circles as well as foster exchange with experts in science and the field. Her area of responsibility includes all […]
Bayer and the Broad Institute of MIT and Harvard have renewed their research alliance, adding five years to a 10-year collaboration that has already yielded three clinical oncology candidates. This research collaboration is aimed at identifying cancer targets and exploring novel therapeutic approaches in oncology with the goal of bringing more medicines to patients.